FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
DALLAS and FORT WORTH, Texas, May 02, 2017 -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced that it will report its first quarter 2017 financial results prior to the opening of U.S. financial markets on Tuesday, May 9, 2017. Neos management will host a conference call and live audio webcast to discuss these results and provide a company update at 8:30 a.m. ET that same day.
The live call may be accessed by dialing (877) 388-8985 for domestic calls, or +1 (562) 912-2654 for international callers, and referencing conference ID number 94755525. A live audio webcast for the conference call will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODTTM, indicated for the treatment of ADHD in patients 6 years of age and older, is the first approved product using the Company’s extended-release (XR)-orally disintegrating tablet (ODT) technology platform. Neos, which is initially focusing on the treatment of ADHD, has filed New Drug Applications with the U.S. Food and Drug Administration for two other branded product candidates that are XR medications in ODT or oral suspension dosage forms. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®, an XR oral suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.1
1Tussionex® is a registered trademark of the UCB Group of Companies.
Contacts: Richard Eisenstadt Chief Financial Officer Neos Therapeutics (972) 408-1389 [email protected] Sarah McCabe Vice President Stern Investor Relations, Inc. (212) 362-1200 [email protected]
